{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:05:19Z","timestamp":1792271119364,"version":"4.4.0"},"reference-count":29,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["3P30CA12443512"],"award-info":[{"award-number":["3P30CA12443512"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5R01HL08977810"],"award-info":[{"award-number":["5R01HL08977810"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5UL1TR003142-03"],"award-info":[{"award-number":["5UL1TR003142-03"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Dutch Research Council","doi-asserted-by":"crossref","award":["452019301"],"award-info":[{"award-number":["452019301"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with amyotrophic lateral sclerosis (ALS) show considerable variation in symptoms. Treatments targeting an overall improvement in symptomatology may not address what the majority of patients consider to be most important. Here, we propose a composite endpoint for ALS clinical trials that weighs the improvement in symptoms compared with what the patient population actually wants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An online questionnaire was sent out to a population-based registry in The Netherlands. Patients with ALS were asked to score functional domains with a validated self-reported questionnaire, and rank the order of importance of each domain. This information was used to estimate variability in patient preferences and to develop the Patient-Ranked Order of Function (PROOF) endpoint.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was extensive variability in patient preferences among the 433 responders. The majority of the patients (62.1%) preferred to prioritise certain symptoms over others when evaluating treatments. The PROOF endpoint was established by comparing each patient in the treatment arm to each patient in the placebo arm, based on their preferred order of functional domains. PROOF averages all pairwise comparisons, and reflects the probability that a patient receiving treatment has a better outcome on domains that are most important to them, compared with a patient receiving placebo. By means of simulation we illustrate how incorporating patient preference may upgrade or downgrade trial results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The PROOF endpoint provides a balanced patient-focused analysis of the improvement in function and may help to refine the risk\u2013benefit assessment of new treatments for ALS.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2021-328194","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T18:28:07Z","timestamp":1639765687000},"page":"539-546","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Composite endpoint for ALS clinical trials based on patient preference: Patient-Ranked Order of Function (PROOF)"],"prefix":"10.1136","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7132-5967","authenticated-orcid":false,"given":"Ruben P A","family":"van Eijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L H","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"key":"2023051800301761000_93.5.539.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)30199-5"},{"key":"2023051800301761000_93.5.539.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31287-4"},{"key":"2023051800301761000_93.5.539.3","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2021.1879865"},{"key":"2023051800301761000_93.5.539.4","unstructured":"European Medicines Agency . Guideline on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis, 2016. Available: https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-amyotrophic-lateral-sclerosis_en.pdf [Accessed 04 May 2021]."},{"key":"2023051800301761000_93.5.539.5","unstructured":"Food drug administration center for drugs evaluation research. guidance for industry: amyotrophic lateral sclerosis: developing drugs for treatment, 2019. Available: https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM596718.pdf [Accessed 04 May 2021]."},{"key":"2023051800301761000_93.5.539.6","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1001\/jamaneurol.2019.4490","article-title":"Development and validation of the Rasch-Built overall amyotrophic lateral sclerosis disability scale (roads)","volume":"77","author":"Fournier","year":"2020","journal-title":"JAMA Neurol"},{"key":"2023051800301761000_93.5.539.7","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410220308"},{"key":"2023051800301761000_93.5.539.8","doi-asserted-by":"publisher","DOI":"10.3109\/21678421.2015.1026829"},{"key":"2023051800301761000_93.5.539.9","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-304701"},{"key":"2023051800301761000_93.5.539.10","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2011-300141"},{"key":"2023051800301761000_93.5.539.11","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.184"},{"key":"2023051800301761000_93.5.539.12","unstructured":"Lu Y , Zhao Q , Zou J . A composite endpoint approach to evaluate treatment benefits based on patient preferences. Under review 2021."},{"key":"2023051800301761000_93.5.539.13","doi-asserted-by":"publisher","DOI":"10.1080\/146608200300079536"},{"key":"2023051800301761000_93.5.539.14","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2011.244939"},{"key":"2023051800301761000_93.5.539.15","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-321138"},{"key":"2023051800301761000_93.5.539.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(99)00210-5"},{"key":"2023051800301761000_93.5.539.17","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2018.1484925"},{"key":"2023051800301761000_93.5.539.18","doi-asserted-by":"publisher","DOI":"10.3109\/21678421.2014.897357"},{"key":"2023051800301761000_93.5.539.19","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-020-00482-z"},{"key":"2023051800301761000_93.5.539.20","unstructured":"Food Drug Administration Center for Drugs Evaluation Research . FDA Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient\u2019s Voice in Medical Product Development and Regulatory Decision Making, 2020. Available: https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical [Accessed 30 August 2021]."},{"key":"2023051800301761000_93.5.539.21","unstructured":"European Medicines Agency . Ich reflection paper on proposed ICH guideline work to advance patient focused drug development, 2020. Available: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-reflection-paper-proposed-ich-guideline-work-advance-patient-focused-drug-development_en.pdf [Accessed 30 Aug 2021]."},{"key":"2023051800301761000_93.5.539.22","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-019-0875-z"},{"key":"2023051800301761000_93.5.539.23","doi-asserted-by":"publisher","DOI":"10.3109\/21678421.2012.762930"},{"key":"2023051800301761000_93.5.539.24","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-320998"},{"key":"2023051800301761000_93.5.539.25","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14195"},{"key":"2023051800301761000_93.5.539.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.04.023"},{"key":"2023051800301761000_93.5.539.27","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-320553"},{"key":"2023051800301761000_93.5.539.28","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-322992"},{"key":"2023051800301761000_93.5.539.29","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008063"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2021-328194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T07:31:07Z","timestamp":1684395067000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2021-328194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,17]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,4,12]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1136\/jnnp-2021-328194"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2021-328194","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,17]]}}}